TCR2 Therapeutics Inc.

09/17/2021 | Press release | Distributed by Public on 09/17/2021 07:09

TCR2 Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors (Form 8-K)